The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: Is there a relationship to dopamine D2 receptor occupancy?

Neuroscience and Biobehavioral Reviews

Volumn 26, Issue 3, 2002, Pages 361-380

  Turrone, Peter ^a,b   Remington, Gary ^a,b,c   Nobrega, José N ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotics; Dopamine receptor occupancy; Intermittent treatment; Tardive dyskinesia; Treatment schedule; Vacuous chewing movements

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT;

DISEASE SEVERITY; DOPAMINE RECEPTOR BLOCKING; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; INVOLUNTARY MOVEMENT; MASTICATION; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TARDIVE DYSKINESIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; HUMANS; HYPERKINESIS; MODELS, ANIMAL; RATS; RECEPTORS, DOPAMINE D2; RISK FACTORS;

EID: 0036106055     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(02)00008-8     Document Type: Review

References (147)

1. Tardive dyskinesia: Pathophysiology and animal models
2. Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench
3. Tardive drug-induced extrapyramidal syndromes
4. Integrating incidence and prevalence of tardive dyskinesia
5. Tardive dyskinesia: Prevalence, incidence, and risk factors
6. Expected incidence of tardive dyskinesia associated with atypical antipsychotics
7. Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: The enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms
8. Tardive dyskinesia
9. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration - Phenomenology, pathophysiology and putative relationship to tardive dyskinesia
10. Neuroleptic side effects: Acute extrapyramidal syndromes and tardive dyskinesia
11. A five-year follow-up study of tardive dyskinesia
12. Prospective study of tardive dyskinesia incidence in the elderly
13. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia
14. Drug holidays: Intermittent pharmacotherapy for psychiatric patients
15. Tardive dyskinesia - Reversible and persistent
16. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao extrapyramidal syndromes study III
17. Pseudoparkinsonism and tardive dyskinesia
18. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications
19. Persistent tardive dyskinesia: Demographic and pharmacological risk factors
20. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis
21. Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol
22. Effects of clozapine and haloperidol on baseline levels of vacuous jaw movements in aged rats
23. Intermittent versus continuous neuroleptic treatment in a rat model
24. Persistent vacuous chewing in rats following neuroleptic treatment: Relationship with dopaminergic and cholinergic function
25. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration
26. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment
27. Mixture in the distribution of haloperidol induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia
28. Intermittent and continuous haloperidol regimens produce different types of oral dyskinesias in rats
29. Persistent oral dyskinesias in haloperidol-withdrawn neonatal 6-hydroxydopaminelesioned rats
30. Persistent spontaneous oral dyskinesias in haloperidol-withdrawn rats neonatally lesioned with 6-hydroxydopamine - Absence of an association with the b-max for [h-3]raclopride binding to neostriatal homog
31. Oral dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid
32. Neurobiochemical changes in tardive dyskinesia
33. The association of tardive dyskinesia and pseudoparkinsonism
34. A model for oral dyskinesia in rats
35. Differential effects of continuous administration for one year of haloperidol or sulpiride on striatal dopamine function in the rat
36. Pharmacological characterization of spontaneous or drug-associated purposeless chewing movements in rats
37. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol
38. Scopolamine fails to diminish chronic haloperidol-induced purposeless chewing in rats
39. Pharmacological characterization of tardive dyskinesia
40. Dyskinetic oral movements in guinea pigs following chronic neuroleptic treatment
41. Delayed appearance of facial tics following chronic fluphenazine administration to guinea pigs
42. Dyskinesias evoked in monkeys by weekly administration of haloperidol
43. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats - Implications for tardive dyskinesia?
44. The significance of dopamine-receptor blockade for the action of neuroleptic drug
45. Dopamine receptors and the dopamine hypothesis of schizophrenia
46. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons
47. Relationship of neuroleptic drugs effects at brain dopamine, serotonin, a-adrenergic, and histamine receptors to clinical potency
48. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis
49. The role of serotonin in antipsychotic drug action
50. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation
51. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
52. Relationship between dopamine D2 receptor occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia
53. An experimental model of tardive dyskinesia
54. Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors
55. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain
56. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study
57. Effects of chronic haloperidol on stress-induced oral behaviour in rats
58. Neurobiological substrates of tardive dyskinesia: The GABA hypothesis
59. Further anomalies in the dopamine receptor supersensitivity hypothesis of tardive dyskinesia
60. Localized changes in GABA receptor-gated chloride channel in rat brain after long-term haloperidol: Relation to vacuous chewing movements
61. Quantitative autoradiography of striatal dopamine D1, D2 and re-uptake sites in rats with vacuous chewing movements
62. D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment
63. Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesia in rats
64. Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias
65. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease
66. Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum
67. Use of positron emission tomography in analyzing receptor function in vivo
68. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects
69. Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia
70. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: A PET study
71. Neuroleptic-induced vacuous chewing movements in rodents: Incidence and effects of long-term increases in haloperidol dose
72. Dose-dependent increases in rat spontaneous chewing rates during long-term administration of haloperidol but not clozapine
73. Autoradiographic mapping of mu opioid receptor changes in rat brain after long-term haloperidol treatment: Relationship to the development of vacuous chewing movements
74. Tardive dyskinesia: Behavioural effects of repeated intracerebroventricular haloperidol injections in rats do not confirm the kindling hypothesis
75. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
76. The dose-response relationship characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration
77. Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats
78. Neurochemical changes in the entopeduncular nucleus and increased oral behaviour in rats treated subchronically with clozapine or haloperidol
79. Chronic oral haloperidol and clozapine in rats: A behavioural evaluation
80. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
81. Effect of chronic olanzapine treatment on striatal synaptic organization
82. Risperidone-induced tardive dyskinesia in first-episode psychotic patients
83. Risperidone and tardive dyskinesia in organic psychosis
84. Tardive dyskinesia during treatment with risperidone
85. Tardive dyskinesia caused by the atypical antipsychotic risperidone and cured by the use of another drug of the same class, olanzapine
86. Tardive dyskinesia due to risperidone
87. Risperidone-induced tardive dyskinesia
88. Neurological side effects in neuroleptic-naïve patients treated with haloperidol or risperidone
89. Effects of chronic administration of low and high dose of risperidone on vacuous chewing movements in rat
90. Drug holidays after onset of oral movements in rats following chronic haloperidol
91. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: A study in three rat strains
92. Estrogen receptor activation and tardive dyskinesia
93. Oral movement patterns induced in rats by local infusions into striatum depend upon the regimen of prior neuroleptic exposure
94. Intermittent versus continuous stimulation: Effect of time interval on the development of sensitization or tolerance
95. Tremorous mouth movements in rats administered chronic neuroleptics
96. Characteristics of oral movements in rats during and after chronic haloperidol and fluphenazine administration
97. Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia
98. Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: Implications for models of tardive dyskinesia
99. The effect of chronic neuroleptic administration on cerebral dopamine receptor function
100. Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration
101. Haloperidol-induced vacuous chewing movements: Suppression by tyrosine
102. Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat
103. Ultrastructural correlates of haloperidol-induced oral dyskinesia and the striatum
104. Neuroleptic-induced chewing movements in the rat are suppressed by peripherally but not centrally administered CCK and abolished by bilateral subdiaphragmatic vagotomy
105. Neurotensin and neurotensin analogues modify the effects of chronic neuroleptic administration in the rat
106. Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment in rats
107. Methylazoxymethanol (MAM)-induced brain lesion and oral dyskinesia in rats
108. Chronic neuroleptic-induced mouth movements in the rat: Suppressed by CCK and selective dopamine D1 and D2 receptor antagonists
109. The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia
110. Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia
111. Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats
112. Effect of dopamine D-1 agonist in rats treated chronically with zuclopenthixol
113. Persistent alterations in dendrites, spines, and dynorphic synapses in the nucleus accumbens shell of rats with neuroleptic-induced dyskinesias
114. The effects of raclopride on vacuous chewing movements in rats following acute administration
115. Effects of ethanol in a putative rodent model of tardive dyskinesia
116. Enhancement of laminar FosB expression in frontal cortex of rats receiving long chronic clozapine administration
117. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): Possible involvement of calcium and nitric oxide
118. Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists
119. Effects of neurotensin in a rodent model of tardive dyskinesia
120. Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin
121. Decreased μ-opiod receptor binding in the globus pallidus of rats treated with chronic haloperidol
122. Effects of chronic naloxone administration on vacuous chewing movements and catalepsy in rats treated with long-term haloperidol decanoate
123. Early suppression of striatal cyclic GMP may pre-determine the induction and severity of chronic haloperidol-induced vacuous chewing movements
124. FosB in rat striatum: Normal regional distribution and enhanced expression after 6-month haloperidol adminstration
125. The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia
126. No changes in dopamine D1 receptor mRNA expressing neurons in the dorsal striatum of rats with oral movements induced by long-term haloperidol administration
127. Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration
128. Striatal enlargement in rats chronically treated with neuroleptic
129. Coeenzyme Q10 does not prevent oral dyskinesias induced by long-term haloperidol treatment in rats
130. Regional brain changes in [3H]SCH binding to dopamine D1, receptors after long-term haloperidol treatment: Lack of correspondence with the development of vacuous chewing movements
131. Failure to down regulate NMDA receptors in the striatum and nucleus accumbens associated with neuroleptic-induced dyskinesia
132. Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol
133. Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia
134. Study of suitability of a rat model for tardive dyskinesia and the preventative effects of various drugs
135. Chronic haloperidol-induced alterations in pallidal GABA and striatal D1-mediated dopamine turnover as measured by dual probe micodialysis in rats
136. Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate
137. The relationship between motor effects in rats following acute and chronic haloperidol treatment
138. Effects of rating parameters on assessment of neuroleptic-induced vacuous chewing movements
139. Oral dyskinesia in rats following brain lesions and neuroleptic drug administration
140. Chronic melperone administration does not enhance oral movements in rats
141. Recording oral activity in rats reveals a long-lasting subsenstivity to haloperidol as a function of duration of previous haloperidol treatment
142. Assessment of striatal extracellular dopamine and dopamine metabolites by micodialysis in haloperidol-treated rats exhibiting oral dyskinesia
143. Tremulous jaw movements in rats: A model of Parkinsonian tremor
144. Striatal binding of 11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: No evidence for altered dopamine D2 receptor binding
145. Acute dystonia induced by neuroleptic drugs